EUVIMEDEUVIMED entdecken
Crossref

Which is the Achilles heel of gastrointestinal stromal tumour and how to use it for the future?—a review of novel therapeutic paradigms

Iván Olivares-Rivas, Alfonso García-Valverde, César Serrano

Gastrointestinal Stromal Tumor · 2022

DOI: 10.21037/gist-21-11 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastrointestinal Stromal Tumor, 2022. Verfasst von Iván Olivares-Rivas und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: The clinical and therapeutic management of gastrointestinal stromal tumours (GISTs) has improved dramatically over the last two decades. Since imatinib approval in the turn of the century, GIST has emerged as a paradigm to investigate and rationally design novel treatments strategies aiming to exploit GIST cells reliance on KIT or platelet-derived growth factor receptor alpha (PDGFRA) oncogenic signalling. However, most patients develop resistance to imatinib and eventually become resistant to all further approved treatments. Additionally, there are patients whose GIST is driven independently of KIT and PDGFRA (wild-type GIST). For this reason, novel therapeutics are needed, especially those that can circumvent therapeutic resistance and target GIST regardless of mutational status. Thus, the objective of this review is to discuss novel biological insights that can be used in the near future to innovate clinically in the treatment of GIST.

Methods

PubMed search, all years considered but articles only in English language. Key Content and Findings: Herein, we discuss novel biological insights that can be used in the near future to innovate clinically, such as targeting or hijacking the ubiquitin-proteasome system (UPS) and further understanding the role of the tumour microenvironment in GIST. Additionally, we find critical to thoroughly study the mechanisms responsible for adaptive resistance to KIT/PDGFRA-targeted inhibition and tumour heterogeneity.

Conclusions

GIST, as any cancer, is a heterogeneous disease. Therefore, the Achilles heel of GIST is multifaceted and will require the development of diverse approaches that can target this disease from different angles.

Zitieren

APA

Olivares-Rivas, I., García-Valverde, A., & Serrano, C. (2022). Which is the Achilles heel of gastrointestinal stromal tumour and how to use it for the future?—a review of novel therapeutic paradigms. Gastrointestinal Stromal Tumor. https://doi.org/10.21037/gist-21-11

Vancouver

Olivares-Rivas I, García-Valverde A, Serrano C. Which is the Achilles heel of gastrointestinal stromal tumour and how to use it for the future?—a review of novel therapeutic paradigms. Gastrointestinal Stromal Tumor. 2022. doi:10.21037/gist-21-11

BibTeX
@article{OlivaresRivas2022,
  author = {Olivares-Rivas, Iván and García-Valverde, Alfonso and Serrano, César},
  title = {Which is the Achilles heel of gastrointestinal stromal tumour and how to use it for the future?—a review of novel therapeutic paradigms},
  journal = {Gastrointestinal Stromal Tumor},
  year = {2022},
  doi = {10.21037/gist-21-11}
}
Kostenlos starten →